Skip to content

Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says

  • by
  • 1 min read

Some analysts have predicted the market for weight-loss drugs could reach $100 billion a year by the end of the decade, with Ozempic maker Novo Nordisk and Mounjaro producer Eli Lilly leading the race. The use of GLP-1s could increase by anywhere between 10 to 70 million consumers by 2028, Goldman Sachs said on Thursday. “If GLP-1 usage ultimately increases by this amount and results in lower obesity rates, we see scope for significant spillovers to the broader economy,” Goldman economists said in a note.

Join the conversation

Your email address will not be published. Required fields are marked *